Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19.

Patients over the age of 60 and patients with chronic kidney disease were less likely to report symptom improvement after starting MOL, although this did not reach statistical significance ( Table 3 ) Risk factors were not assessed for SOT and N/R, as data was not adequately collected for these two patient groups and risk stratification could not be applied. 5.

also in 111,027 other papers